Enclomiphene and Letrozole Interaction

Avoid
Mechanism-based 64% confidence

Enclomiphene and Letrozole have a potentially harmful interaction with 64% confidence. Both Enclomiphene and Letrozole carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the gonads and pituitary, so monitoring these systems is recommended.

Compound Profiles

Enclomiphene

Selective Estrogen Receptor Modulator | Testosterone & Fertility Support

Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH release. This disinhibition increases pulsatile GnRH secretion, which in turn stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Half-life: ~10 hours Typical dose: 12.5-25mg oral daily pct, sexual health
estrogen receptorserotonin receptor hepatotoxicpct agentteratogenic
View full profile

Letrozole

Aromatase Inhibitor | Potent Estrogen Suppression

Letrozole competitively and reversibly binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), inhibiting its catalytic activity with greater potency than any other commercially available aromatase inhibitor. Aromatase catalyzes the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain.

Half-life: ~2 days (48 hours) Typical dose: 0.25-0.5mg EOD (on-cycle); 2.5mg/day (medical) pct, anabolic
aromatase androgenicaromatase inhibitorhepatotoxichpta suppressive
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Pituitary
low
Heart
low

Shared Safety Flags

2x 2 hepatotoxic compounds (Enclomiphene, Letrozole). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds share the pct-agent safety flag (Enclomiphene, Letrozole). Monitor accordingly.
2x 2 compounds share the teratogenic safety flag (Enclomiphene, Letrozole). Monitor accordingly.

Frequently Asked Questions

Can I take Enclomiphene with Letrozole?

Combining Enclomiphene with Letrozole is not recommended. Both Enclomiphene and Letrozole carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Enclomiphene and Letrozole safe together?

This combination carries significant risk. Both Enclomiphene and Letrozole carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Enclomiphene and Letrozole?

Both Enclomiphene and Letrozole carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Enclomiphene and Letrozole?

Enclomiphene has a half-life of ~10 hours and Letrozole has a half-life of ~2 days (48 hours). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Enclomiphene vs Letrozole

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.